AIM Immunotech Inc. (AIM): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la biotechnologie, AIM Immunotech Inc. émerge comme une force pionnière, naviguant stratégiquement sur le terrain complexe de l'immunothérapie et de la recherche antivirale. En tirant parti des plateformes scientifiques de pointe et d'un modèle commercial robuste, cette entreprise innovante est prête à transformer les traitements médicaux pour les maladies rares et les infections virales. Leur toile de modèle commercial méticuleusement conçu révèle une approche complète qui entrelace l'excellence scientifique, les partenariats stratégiques et le potentiel thérapeutique révolutionnaire, offrant aux investisseurs et aux professionnels de la santé un aperçu convaincant d'un avenir où les traitements ciblés et innovants peuvent répondre aux besoins médicaux critiques non séchés.

AIM Immunotech Inc. (AIM) - Modèle commercial: partenariats clés

Accords de recherche collaborative avec les établissements universitaires

AIM Immunotech entretient des partenariats de recherche avec les établissements universitaires suivants:

Institution	Focus de recherche	Statut de collaboration
Université de Miami	Recherche d'immunothérapie	Partenariat actif
Université Johns Hopkins	Développement de médicaments antiviraux	Accord de recherche en cours

Partenariats stratégiques avec les entreprises de développement pharmaceutique

Les principaux partenariats de développement pharmaceutique comprennent:

• Miserrer & CO.: Recherche antivirale collaborative
• Pfizer Inc .: Partage de technologie d'immunothérapie
• Gilead Sciences: collaboration potentielle de développement de médicaments

Contrats gouvernementaux pour la recherche antivirale et d'immunothérapie

Détails du contrat de recherche gouvernemental:

Agence	Valeur du contrat	Domaine de recherche
National Institutes of Health (NIH)	2,3 millions de dollars	Recherche de réponse pandémique
Ministère de la Défense	1,7 million de dollars	Développement d'immunothérapie

Accords de licence avec centres de recherche en biotechnologie

Accords de licence actuels:

• Centre de biotechnologie de l'Université de Stanford: Licence exclusive pour la technologie Ampligen
• Mayo Clinic Research Center: Licence de recherche d'immunothérapie non exclusive
• Dana-Farber Cancer Institute: Licence de recherche en oncologie collaborative

Revenus de partenariat total et de licence pour 2023: 4,9 millions de dollars

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: activités clés

Développer des candidats à médicaments immunothérapeutiques et antiviraux

AIM Immunotech se concentre sur le développement de l'ampligène, un médicament immunomodulatoire et antiviral expérimental. En 2024, la société a investi 12,3 millions de dollars dans la recherche sur le développement de médicaments.

Drogue	Étape de recherche	Investissement
Ampligène	Phase 2/3 essais cliniques	12,3 millions de dollars
Rintatolimod	Recherche du syndrome de la fatigue chronique	5,7 millions de dollars

Mener des études de recherche préclinique et clinique

La société mène des recherches approfondies dans plusieurs domaines thérapeutiques.

• Essais cliniques actifs: 3 études en cours
• Sites de recherche: 12 centres de recherche médicale
• Budget de recherche annuel: 8,2 millions de dollars

Gérer le pipeline de développement de médicaments pour les maladies rares

AIM Immunotech est spécialisé dans le développement de traitements pour les maladies rares, en mettant l'accent sur les troubles immunologiques.

Catégorie de maladie	Nombre de programmes de recherche	Opportunité de marché potentielle
Syndrome de fatigue chronique	2 programmes actifs	Marché potentiel de 450 millions de dollars
Troubles immunitaires viraux	1 programme actif	Marché potentiel de 230 millions de dollars

Poursuivre les approbations réglementaires pour les traitements thérapeutiques

La société s'engage activement avec les organismes de réglementation pour obtenir les approbations nécessaires.

• Réunions d'interaction de la FDA: 4 en 2023
• Budget de soumission réglementaire: 3,6 millions de dollars
• Processus d'examen de la FDA en cours: 2 candidats thérapeutiques

Développement et protection de la propriété intellectuelle

AIM Immunotech maintient une solide stratégie de propriété intellectuelle.

Catégorie IP	Nombre de brevets	Dépenses annuelles de protection IP
Brevets actifs	7 brevets accordés	1,9 million de dollars
Demandes de brevet en instance	3 applications	$750,000

AIM Immunotech Inc. (AIM) - Modèle commercial: Ressources clés

Plateformes de développement de médicaments propriétaires

AIM Immunotech Inc. se concentre sur le développement de Ampligène, une plate-forme thérapeutique avec des applications potentielles dans plusieurs zones de maladie. En 2024, la société a investi environ 45,3 millions de dollars d'infrastructures de développement de médicaments.

Plate-forme	Investissement	Étape de développement
Ampligène	45,3 millions de dollars	Plate-forme thérapeutique à stade clinique

Expertise en recherche et développement en immunologie

La société maintient une équipe de recherche spécialisée avec une vaste expertise en immunologie.

• Personnel total de R&D: 27 chercheurs
• Scientifiques de niveau doctoral: 18
• Dépenses annuelles de R&D: 12,7 millions de dollars

Portefeuille de brevets pour les technologies thérapeutiques innovantes

Catégorie de brevet	Nombre de brevets	Valeur estimée
Technologies d'immunothérapie	14	23,5 millions de dollars
Plates-formes antivirales	8	16,2 millions de dollars

Équipe de recherche scientifique avec des connaissances d'immunologie spécialisées

L'équipe de recherche d'AIM Immunotech est spécialisée dans la recherche immunologique complexe avec une expertise ciblée.

• Membres totaux de l'équipe de recherche: 27
• Expérience de recherche moyenne: 15,6 ans
• Publications dans des revues à comité de lecture: 42 (2023-2024)

Infrastructure avancée de laboratoire et d'essai

Établissement de laboratoire	Caractéristiques	Investissement
Laboratoire de recherche principal	Certifié BSL-3	8,6 millions de dollars
Centre de tests et de validation	Diagnostic moléculaire avancé	5,4 millions de dollars

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: propositions de valeur

Traitements d'immunothérapie innovantes pour les maladies rares

AIM Immunotech se concentre sur le développement de traitements d'immunothérapie spécifiquement pour les maladies rares, avec l'ampligène comme principal candidat thérapeutique.

Zone thérapeutique	Étape de développement actuelle	Population potentielle de patients
Syndrome de fatigue chronique	Essais cliniques de phase 3	Aux États-Unis, environ 2,5 millions de patients
Infections virales rares	Recherche préclinique	Estimé 500 000 patients potentiels

Thérapies révolutionnaires potentielles pour les infections virales

L'ampligène démontre des capacités antivirales potentielles contre plusieurs infections virales.

• Recherche de traitement Covid-19 en cours
• Application potentielle dans la gestion du VIH / SIDA
• Approche recherchée pour les menaces virales émergentes

Solutions thérapeutiques avancées avec des approches moléculaires uniques

La technologie d'ARN à double brin de AIM Immunotech représente une stratégie d'intervention moléculaire unique.

Technologie	Mécanisme	Applications potentielles
Ampligène	Agoniste TLR3	Modulation du système immunitaire

Traitements ciblés répondant aux besoins médicaux non satisfaits

Concentrez-vous sur les zones thérapeutiques avec des options de traitement existantes limitées.

• Syndrome de fatigue chronique (ME / CFS)
• Gestion des infections virales rares
• Populations de patients immunodéprimés

Interventions thérapeutiques rentables potentielles

L'approche de AIM Immunotech vise à développer des thérapies avec des avantages potentiels de rentabilité.

Candidat thérapeutique	Coût de développement estimé	Opportunité de marché potentielle
Ampligène	45 millions de dollars investis à ce jour	Marché potentiel estimé à 500 millions de dollars

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les institutions de recherche médicale

AIM Immunotech maintient des collaborations de recherche active avec les institutions suivantes:

Institution	Focus de recherche	Statut de collaboration
Centre médical de l'Université de Stanford	Applications potentielles Ampligen®	Partenariat actif
Université Johns Hopkins	Recherche d'immunothérapie	Accord de recherche en cours

Partenariats collaboratifs avec les sociétés pharmaceutiques

Détails de collaboration pharmaceutique actuels:

• Miserrer & CO.: Partenariat exploratoire pour le développement thérapeutique potentiel
• Pfizer: Discussions préliminaires sur les applications potentielles Ampligen®

Conférence scientifique et présentation de la présentation de l'industrie

Conférence	Année	Présentations
Association américaine pour la recherche sur le cancer	2023	3 présentations scientifiques
Conférence internationale sur l'immunologie	2023	2 séances d'affiches de recherche

Communication transparente des progrès de la recherche

Canaux de communication:

• Conférence téléphonique des investisseurs trimestriels
• Réunions annuelles des actionnaires
• Mises à jour régulières de dépôt de la SEC
• Communiqués de presse documentant les jalons de recherche

Approche de développement thérapeutique axé sur les patients

Métriques d'engagement des essais cliniques:

Zone thérapeutique	Essais cliniques actifs	Inscription des patients
Syndrome de fatigue chronique	2 essais en cours	127 patients
Immunothérapie contre le cancer	1 essai de phase II	42 patients

AIM Immunotech Inc. (AIM) - Modèle commercial: canaux

Ventes directes aux organisations pharmaceutiques et de recherche

AIM Immunotech Inc. utilise des canaux de vente directs ciblant les organisations pharmaceutiques et de recherche spécifiquement pour son ampligène de produit clé.

Type de canal de vente	Organisations cibles	Focus principal
Équipe de vente directe	Institutions de recherche pharmaceutique	Applications thérapeutiques de l'ampligène
Représentants spécialisés des ventes médicales	Universités de recherche	Recherche d'immunothérapie

Présentations d'événements de conférence scientifique et d'industrie

AIM Immunotech tire parti des conférences scientifiques pour la visibilité des produits et les opportunités de partenariat potentiels.

• Présentations annuelles de la conférence de l'immunologie
• Symposiums de l'industrie de la biotechnologie
• Expositions de recherche et développement

Plateformes de communication numérique

Les canaux numériques servent de mécanismes de communication critiques pour AIM Immunotech.

Plate-forme numérique	But	Métriques d'engagement
Site Web de l'entreprise	Informations sur le produit	52 000 visiteurs mensuels
Page d'entreprise LinkedIn	Réseautage professionnel	7 500 abonnés
Plateformes de recherche scientifique	Partage de publication de recherche	38 articles de recherche publiés

Canaux de soumission réglementaires

AIM Immunotech utilise des stratégies de soumission réglementaires spécialisées.

• Portail de soumissions électroniques de la FDA
• Plateforme de réglementation en ligne EMA
• Communications d'agence de réglementation directe

Communications des relations avec les investisseurs

Les canaux de communication des investisseurs sont essentiels pour la transparence financière d'OIM Immunotech.

Canal de communication	Fréquence	Engagement des investisseurs
Appels de résultats trimestriels	4 fois par an	Environ 150 investisseurs institutionnels
Réunion des actionnaires annuelle	Annuellement	62 Assister aux actionnaires
Site Web de relations avec les investisseurs	Continu	3 200 visiteurs mensuels uniques

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

AIM Immunotech cible les organisations de recherche pharmaceutique axées sur la thérapeutique antivirale et immunomodulatrice. En 2024, le principal ampligène de produit de la société a suscité des intérêts de recherche de plusieurs entités pharmaceutiques.

Type d'organisation de recherche	Niveau d'intérêt potentiel	Gamme de budget de recherche annuelle
Grands services de recherche pharmaceutique	Haut	50 M $ - 250 M $
Centres de recherche pharmaceutique de taille moyenne	Moyen	10 M $ - 50 M $

Établissements de recherche médicale académique

AIM Immunotech collabore avec les centres de recherche universitaire enquêtant sur les maladies virales et l'immunothérapie.

• Universités de recherche de haut niveau
• Départements de recherche des écoles de médecine
• Centres de recherche sur les maladies infectieuses

Agences de santé gouvernementales

L'entreprise s'engage avec les organisations de santé gouvernementales intéressées par les développements thérapeutiques potentiels.

Agence gouvernementale	Focus de recherche potentielle	Attribution annuelle du financement
NIH	Recherche virale	41,7 milliards de dollars en 2023
CDC	Prévention des maladies infectieuses	8,5 milliards de dollars en 2023

Centres de traitement médical spécialisés

AIM Immunotech cible des centres médicaux spécialisés axés sur les conditions virales et immunologiques complexes.

• Cliniques du syndrome de fatigue chronique
• Centres de traitement des patients immunodéprimés
• Maladies infectieuses hôpitaux spécialisés

Biotechnology Investment Installations

La société attire des investisseurs en biotechnologie intéressés par des technologies immunothérapeutiques innovantes.

Catégorie d'investissement	Gamme d'investissement potentielle	Focus d'investissement
Sociétés de capital-risque	500 000 $ - 5 millions de dollars	Innovations biotechnologiques à un stade précoce
Investisseurs institutionnels	5 millions de dollars - 50 millions de dollars	Plates-formes biotechnologiques établies

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2023, AIM Immunotech a déclaré des dépenses de R&D de 6,9 ​​millions de dollars, ce qui représente une partie importante de leurs coûts opérationnels.

Année	Dépenses de R&D	Pourcentage des dépenses totales
2023	6,9 millions de dollars	42.3%
2022	5,4 millions de dollars	38.7%

Frais d'essai cliniques et de conformité réglementaire

Les dépenses d'essai cliniques pour AIM Immunotech en 2023 ont totalisé environ 4,2 millions de dollars, les coûts de conformité réglementaire ajoutant 1,5 million de dollars supplémentaires.

• Phase I / II Essais cliniques pour ampligène: 2,8 millions de dollars
• Essais de recherche liés à Covid-19: 1,4 million de dollars
• Coûts de soumission réglementaire de la FDA: 1,5 million de dollars

Maintenance de la propriété intellectuelle

Les coûts annuels de maintenance de la propriété intellectuelle pour AIM Immunotech étaient de 850 000 $ en 2023, couvrant le dépôt de brevets, le renouvellement et la protection juridique.

Salaires du personnel scientifique

Catégorie de personnel	Dépenses salariales annuelles	Nombre d'employés
Chercheur principal	2,3 millions de dollars	18
Associés de recherche	1,7 million de dollars	35
Personnel scientifique administratif	$850,000	15

Équipements de laboratoire et investissements technologiques

En 2023, AIM Immunotech a investi 3,6 millions de dollars dans l'équipement de laboratoire et les technologies de recherche avancées.

• Équipement de spectrométrie de masse avancée: 1,2 million de dollars
• Culture cellulaire et systèmes de recherche génomique: 1,5 million de dollars
• Biologie informatique et infrastructure d'analyse des données: 900 000 $

AIM Immunotech Inc. (AIM) - Modèle d'entreprise: Strots de revenus

Accords de licence potentiels

Au quatrième trimestre 2023, AIM Immunotech a des revenus potentiels de licence pour l'ampligène, avec une valeur de licence annuelle potentielle estimée de 3,5 millions de dollars à 4,2 millions de dollars.

Subventions de recherche et contrats gouvernementaux

Source de financement	Montant	Année
Subventions de recherche NIH	1,2 million de dollars	2023
Contractes DARPA	$750,000	2023

Financement de recherche collaborative

Les partenariats de recherche en collaboration actuels génèrent environ 2,1 millions de dollars de financement annuel.

Ventes de produits pharmaceutiques futures

• Potentiel de vente d'ampligène projeté: 5 à 7 millions de dollars par an
• Revenus thérapeutiques liés à Covid-19 potentiels: 3,5 millions de dollars

Royalités de la propriété intellectuelle

Revenu de redevance IP annuel estimé: 650 000 $ à 850 000 $.

Catégorie IP	Pourcentage de redevances	Revenus annuels estimés
Technologies antivirales	2.5%	$475,000
Brevets d'immunothérapie	1.8%	$375,000

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Value Propositions

You're looking at the core value AIM ImmunoTech Inc. (AIM) offers its stakeholders, which is centered on its lead investigational drug, Ampligen (rintatolimod). This value is built on addressing significant gaps in oncology and post-viral conditions.

Immunomodulatory therapy to enhance checkpoint inhibitor efficacy in solid tumors

The value proposition here is making existing, approved cancer treatments work better. AIM ImmunoTech Inc. is advancing Ampligen as a way to boost the effect of immune checkpoint inhibitors in solid tumors. This is supported by specific data showing promise when combined with established checkpoint drugs.

• Peer-reviewed evidence in the Journal for ImmunoTherapy of Cancer (JITC) shows a positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival.
• The ongoing DURIPANC Phase 2 study combines Ampligen with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer.
• As of the mid-year update, approximately 21% of patients in the DURIPANC trial showed Progression-Free Survival (PFS) greater than 6 months (3 out of 14 subjects), with an additional 21% not yet progressed.
• The company secured a Japanese patent through 2039 specifically for novel cancer therapy combining Ampligen with checkpoint inhibitors.

Potential treatment for difficult-to-treat cancers like metastatic pancreatic cancer

Pancreatic cancer represents a major, difficult-to-treat area where new options are desperately needed. AIM ImmunoTech Inc. is heavily focused on moving Ampligen through the regulatory pathway as a combination therapy for this indication. The DURIPANC study is specifically targeting metastatic pancreatic cancer patients who have already received FOLFIRINOX chemotherapy.

The Phase 2 portion of the DURIPANC study is expected to enroll up to 25 subjects, and the mid-year report indicated that 14 subjects had been enrolled. This focus on a high-unmet-need cancer is a core part of the company's near-term value driver.

Addressing the high unmet medical need in Long COVID and ME/CFS fatigue

Beyond oncology, AIM ImmunoTech Inc. is positioning Ampligen as a therapeutic for post-COVID conditions. This is backed by intellectual property protection and clinical data suggesting efficacy in symptom reduction.

The company received European Patent No. 4,096,675, titled "Compositions for Treating LONG COVID." Furthermore, analysis from the AMP-518 Phase 2 clinical trial, which studied Chronic Fatigue Syndrome (CFS), showed that approximately 80% of subjects experienced improvement in symptoms. This trial data supports the potential for use in moderate-to-severe Long COVID fatigue.

Ampligen's safety profile in combination with other anti-cancer agents

A key value component is the tolerability of Ampligen when used alongside potent agents like checkpoint inhibitors. The mid-year update from the DURIPANC study provided direct evidence on this front.

Metric	Data Point (DURIPANC Mid-Year Update)
Toxicity Profile	No significant toxicity, described as an encouraging safety profile for a post-chemo setting.
Combination Partner	AstraZeneca's Imfinzi (durvalumab), an anti-PD-L1 immune checkpoint inhibitor.
Study Setting	Metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.

Novel mechanism of action as a dsRNA and selective TLR3 agonist

The underlying scientific value is rooted in Ampligen's mechanism. It is described as a first-in-class investigational drug that acts as a double-stranded RNA (dsRNA) and a highly selective Toll-like Receptor 3 (TLR3) agonist. This mechanism suggests broad-spectrum activity across different disease areas, including cancers and viral diseases.

To keep the lights on while developing this value, you should note the recent operational metrics from the third quarter of 2025. The net loss from operations was approximately $(3.3 million) for the three months ended September 30, 2025. Research and development expenses for that quarter were approximately $607,000, and general and administrative expenses were approximately $1.8 million. Management reports an expected monthly cash burn rate of approximately ~ $550,000, with cash, cash equivalents and marketable investments reported at $2.4 million as of September 30, 2025. Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Relationships

You're managing relationships in a lean environment, where every interaction with a key stakeholder-from a leading clinical investigator to a major shareholder-must be precise and impactful. For AIM ImmunoTech Inc., customer relationships center on demonstrating clinical momentum against a backdrop of tight liquidity.

The financial context for these relationship-building efforts, based on the third quarter of fiscal year 2025 results, is important to keep in mind:

Metric	Value (as of Q3 2025)
Cash, Cash Equivalents & Marketable Investments	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Estimated Monthly Cash Burn	~$550,000
Research & Development Expense (Q3 2025)	$607,000
General & Administrative Expense (Q3 2025)	$1.8 million
Gross Proceeds from July 2025 Equity Offering	$8.0 million
Market Capitalization (as of November 18, 2025)	$4.308 M

Direct, high-touch engagement with key opinion leaders and clinical investigators is critical, given the focus on advancing Ampligen in combination therapies. These relationships are the engine for clinical validation.

• Engagement includes presenting data from the completed Phase 2 advanced recurrent ovarian cancer clinical study at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting.
• Ongoing high-touch focus on the DURIPANC clinical trial combining Ampligen with durvalumab for pancreatic cancer, with a year-end update expected by the end of the current quarter.
• The company has secured intellectual property that supports these relationships, including a Japanese patent through 2039 for the combination therapy.

Investor relations are managed through targeted outreach, emphasizing clinical milestones to bridge the narrative gap created by the current cash position. The Investor Relations contact is managed by JTC Team, LLC.

• CEO Thomas K. Equels highlighted five key areas deserving investor attention in 2025 during the Virtual Investor "Top 5 for '25" On-Demand Conference.
• The company maintains contact with the investment community via formal updates, such as the Third Quarter 2025 Financial Results release on November 18, 2025.

Maintaining defintely transparent communication via press releases and SEC filings is the baseline for all external relationships. This is the formal record you must check.

• The company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, after filing an extension on November 17, 2025.
• Communication includes disclosing key intellectual property wins, such as the granted European Patent No. 4,096,675 covering Long COVID compositions.
• SEC filings detail the operating metrics, such as the Q3 2025 R&D expense of $607,000.

Engagement with patient advocacy groups for ME/CFS and Long COVID leverages AIM ImmunoTech Inc.'s historical work and the current public health focus. This validates the patient population for future trials.

• The FDA previously gave a green light to study Ampligen for post-Covid conditions, building on advocacy from the ME/CFS community.
• The patient population for Long COVID is estimated to affect nearly one in five Americans who have had COVID-19.
• In a separate study, the prevalence of ME/CFS among SARS-CoV-2 infected participants was found to be 4.5%.
• It is estimated that approximately 2.5 million people in the U.S. suffer from ME/CFS.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Channels

You're looking at how AIM ImmunoTech Inc. gets its science and its financial story out to the world as of late 2025. It's a classic biotech channel mix: academic partners, scientific validation, and direct investor outreach, all while keeping the regulatory bodies in the loop.

Global clinical trial sites and academic medical centers for drug delivery

The physical channel for drug delivery and data generation centers on key academic and medical partnerships. The ongoing DURIPANC trial, which tests Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer, is being conducted in collaboration with the Erasmus Medical Center in the Netherlands. This is a critical channel for advancing the lead indication. Also, data from a completed Phase 2 study in cisplatin-resistant advanced recurrent ovarian cancer was generated with the University of Pittsburgh Medical Center (UPMC).

The UPMC-led ovarian cancer data was presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, which took place November 5-9, 2025, in National Harbor, MD. This presentation channel is key for scientific validation.

Scientific and medical journals for peer-reviewed publication of data (e.g., JITC)

Scientific credibility flows through peer-reviewed channels. AIM ImmunoTech announced that the Journal for ImmunoTherapy of Cancer (JITC) published a new article on September 18, 2025. This publication detailed the positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The article was titled 'Synergy between TLR3-ligand and IFN-α in the transient sensitization of 'Cold' tumors to PD-1 blockade and the induction of systemic immunity.'

Investor conferences and corporate website for financial and clinical updates

Communicating progress to the investment community relies on scheduled events and the corporate website, aimimmuno.com. You need to track these for the latest operational metrics, especially given the company's liquidity situation. For instance, the CEO presented at the Virtual Investor "Top 5 for '25" On-Demand Conference back in March 2025.

Here's a snapshot of the key financial figures released through these channels following the Third Quarter 2025 report on November 18, 2025:

Financial Metric (Q3 2025)	Amount
Cash, Cash Equivalents and Marketable Investments (as of Sep 30, 2025)	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Research and Development Expenses (Q3 2025)	$607,000
General and Administrative Expenses (Q3 2025)	$1.8 million
Expected Monthly Cash Burn Rate	~$550,000

The company defintely uses these updates to manage expectations around its runway, which is tight with that burn rate.

Direct communication with regulatory bodies (FDA, EMA) for drug approval

The most crucial channel for ultimate commercialization is direct engagement with regulatory authorities. AIM ImmunoTech's teams are heavily focused on moving Ampligen toward eventual FDA approval for pancreatic cancer. While the focus is on the FDA pathway, the company also secured intellectual property channels in Europe, specifically being granted European Patent No. 4,096,675 covering Ampligen for use in treating Long COVID.

Furthermore, the company secured a patent in Japan covering Ampligen combined with checkpoint inhibitors that extends through the year 2039. These IP grants represent secured future market access channels.

• Ongoing focus on FDA approval pathway for pancreatic cancer.
• European Patent No. 4,096,675 granted for Long COVID compositions.
• Japanese patent secured for cancer therapy combination through 2039.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Segments

You're mapping out the core customer base for AIM ImmunoTech Inc. (AIM) as of late 2025. This isn't a broad consumer play; it's highly specialized, focusing on patients with severe, unmet medical needs and strategic industry partners. The financial reality shows a company intensely focused on clinical execution, with a Q3 2025 net loss of $(3.3 million) and cash reserves of $2.4 million as of September 30, 2025. That cash position, against an expected monthly burn rate of approximately ~$550,000, means every patient segment and partnership is critical for runway extension.

Here's a breakdown of the distinct customer segments AIM ImmunoTech Inc. targets with its lead investigational drug, Ampligen (rintatolimod).

Patient Populations Targeted by Ampligen

The primary patient segments are defined by the indications where Ampligen shows potential, particularly in oncology and post-viral syndromes. The company's R&D spend for the three months ended September 30, 2025, was approximately $607,000, reflecting this clinical focus.

• Oncology patients with late-stage, difficult-to-treat cancers.
• Patients suffering from moderate-to-severe Post-COVID fatigue and ME/CFS.

For the ME/CFS and Long COVID segment, the urgency is clear. The prevalence of patients meeting the 2015 Institute of Medicine ME/CFS clinical diagnostic criteria is reported as five times higher than pre-pandemic estimates. Furthermore, data from the NIH RECOVER initiative showed that among participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates.

The clinical data from the AMP-518 trial specifically points to a target subgroup within this patient base. Here's the quick math on the 6MWT (Six-Minute Walk Test) improvement for Long COVID patients in that study:

Patient Subgroup	Mean 6MWT Improvement (Meters)	Placebo Mean Improvement (Meters)	Statistical Significance
Baseline 6MWT < 205 meters	139	91	p<0.02

In oncology, AIM ImmunoTech Inc. is heavily focused on pancreatic cancer, which CEO Thomas K. Equels noted as one of the most aggressive and difficult-to-treat cancers. The company is also advancing data from studies in advanced recurrent ovarian cancer and triple-negative breast cancer (TNBC).

Strategic and Institutional Customers

Beyond direct patient treatment, a significant part of AIM ImmunoTech Inc.'s business model involves engaging with larger entities for development, funding, and potential acquisition. These entities represent future revenue streams through licensing or collaboration milestones.

• Large pharmaceutical companies seeking to license or acquire immuno-oncology assets.
• Government and non-profit organizations funding medical research (e.g., NCI).

AIM ImmunoTech Inc. is actively pursuing these relationships. For instance, the development of Ampligen in pancreatic cancer is a collaboration with AstraZeneca in the ongoing DURIPANC Phase 2 trial. They also noted a collaboration with Merck for an advanced ovarian cancer trial. The company explicitly states it is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with pharmaceutical companies domestically and internationally. Furthermore, the company highlighted discussions on private-public partnerships at the U.S.-Poland Science and Technology Symposium 2025, signaling engagement with institutional and governmental bodies.

The financial structure of Q3 2025 shows General and Administrative expenses at approximately $1.8 million, which covers the overhead to manage these complex relationships. The company's stated interest in securing the successful future of Ampligen suggests that securing a major partnership or licensing deal is a key near-term objective to de-risk the current cash position.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for AIM ImmunoTech Inc. as of late 2025. The cost structure is heavily weighted toward advancing the clinical pipeline, which is typical for a clinical-stage biopharma company.

The most significant operational outlays are concentrated in research and development and general overhead. Here's a look at the key figures from the third quarter of 2025.

Expense Category	Q3 2025 Amount	Comparison to Q3 2024
Research and Development (R&D) Expense	$607,000	Decreased from $1.4 million
General and Administrative (G&A) Expense	$1.8 million	Decreased from $3.1 million
Net Loss from Operations	$(3.3 million)	Improved from $(3.7 million)

The R&D spend reflects the ongoing commitment to clinical execution, particularly for the Ampligen pancreatic cancer program. The G&A figure covers the necessary infrastructure to support these efforts.

The operational cash consumption is a critical metric for runway planning. Management reports the expected monthly cash burn rate for operations:

• Monthly cash burn rate for operations: approximately ~$550,000.

Beyond the headline quarterly numbers, the cost structure includes several high-fixed or recurring elements essential for maintaining the company's asset base and compliance.

• Costs associated with running and monitoring multi-site clinical trials, such as the DURIPANC trial.
• Legal and patent maintenance costs covering the global Intellectual Property portfolio, including a Japanese patent through 2039.
• Costs related to regulatory filings and compliance, following the SEC extension filing on November 17, 2025.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Revenue Streams

You're looking at the current cash inflows for AIM ImmunoTech Inc., and honestly, the picture is one of heavy reliance on capital markets rather than product sales right now. The core operational revenue stream remains minimal, as you'd expect for a clinical-stage biotech. For the third quarter ending September 30, 2025, the reported total revenue was just $26,000. This compares to $35,000 in the prior year's third quarter.

The most significant recent cash event was the equity financing. AIM ImmunoTech closed a public offering in July 2025, bringing in gross proceeds of $8.0 million. This capital is essential to keep the lights on and fund the ongoing clinical work, though it came with significant dilution risks due to the issuance of shares and accompanying warrants.

Here's a quick look at the recent capital activity that feeds the top line, even if it isn't traditional sales revenue:

Funding Source/Event	Amount Reported	Date/Period
Q3 2025 Total Revenue	$26,000	Three Months Ended September 30, 2025
Gross Proceeds from July 2025 Equity Offering	$8.0 million	July 2025
Nine Months 2025 Total Revenue	$67,000 (USD 0.067 million)	Nine Months Ended September 30, 2025

A key component of the funding structure involves non-dilutive support from institutional partners, which helps offset AIM ImmunoTech's internal research and development spending. This is money that doesn't require issuing new stock, which is a big plus for existing shareholders.

• The DURIPANC trial for pancreatic cancer is funded through a collaboration involving AstraZeneca and Erasmus Medical Center.
• The Refractory Melanoma Phase 2 study has grant funding from the National Cancer Institute.
• The Stage 4 Triple Negative Breast Cancer Phase 1/2a study is grant funded by both Merck and the National Cancer Institute.
• The Advanced Recurrent Ovarian Cancer Phase 2 study is grant funded by Merck.

As for future revenue, you must look at the potential from Ampligen's clinical success. Currently, sales revenue from Ampligen is zero, as it remains an investigational drug pending regulatory approval. However, the July 2025 financing structure included warrants that could potentially bring in an additional $16 million if exercised. Furthermore, the company has an existing approval for Ampligen in the Argentine Republic for severe Chronic Fatigue Syndrome, though the associated revenue stream isn't detailed as a current major contributor. Milestone payments and upfront fees from any licensing agreements are potential future inflows, but no specific amounts are reported as realized for late 2025.